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It has been proposed that ghrelin induces food intake
by a mechanism due to the stimulation of hypothala-
mic NPY-ergic activity. It is recognized that bilateral
adrenalectomy (ADX) enhances hypothalamic CRH-
ergic function and reduces appetite. Thus, the aim of
the present study was to test whether, icv-administered,
ghrelin modulates NPY- and CRH-ergic functions after
food restriction (FR) and glucocorticoid deprivation. For
this purpose, 1 µg ghrelin was administered icv to ad
libitum (AL) eating and to corticosterone (B)-depleted
(ADX) and -replete (sham and ADX+B) male animals
habituated, for 15 d, to FR. Food intake, hypothalamic
function, and peripheral ghrelin, ACTH, and B con-
centrations were evaluated 2 h after ghrelin adminis-
tration. Results indicate that while icv ghrelin treatment
stimulated 2-h food intake in AL rats, it failed to do so
in sham- and ADX+B-FR animals; moreover, 2-h food
intake was inhibited by icv ghrelin treatment in ADX-
FR rats. Regarding peripheral hormone levels: (a) basal
circulating ghrelin levels, already enhanced (vs AL rats)
by FR, significantly increased 2 h after icv ghrelin treat-
ment in AL and sham-FR rats; (b) central ghrelin treat-
ment stimulated ACTH secretion in circulation of AL
and glucocorticoid-replete-FR rats; and (c) B circulat-
ing levels remained unchanged after ghrelin treat-
ment, although they were in relation to the food intake
condition of rats. Finally, hypothalamic NPY mRNA
expression was enhanced by FR and, in response to icv
ghrelin treatment, it decreased in ADX-FR rats only.
ADX-enhanced hypothalamic CRH mRNA levels were
reduced by ghrelin icv administration only when ani-
mals received B replacement therapy. Our data indi-
cate an inhibitory effect of hypothalamic ghrelin on
NPY-ergic activity in FR rats lacking endogenous gluco-
corticoid.
Key Words: HPA axis; energy balance; leptin; ghrelin-
R1a; GC-R.
Introduction
Ghrelin, a peptide mainly expressed in the stomach (1),
is considered, at this time, the most relevant peripheral hun-
ger signal (2,3). Once this endogenous ligand of the growth
hormone secretagogue receptor (GHS-R) (1) reaches high
circulating concentrations, it is sensed at the hypothalamic
level, thus modulating food intake (4–6).
In mammals, fasting/starvation-related high plasma ghre-
lin concentrations (7,8) is a characteristic associated with
increased circulating glucocorticoid levels (9), while both
decrease after food intake (10–12). Moreover, the inverse
relationship in the circulating levels of ghrelin and leptin
(2) clearly indicate that an inappropriate signaling of these
two peptides could have physiopathological implications.
Thus, the relation between hypothalamo–pituitary–adrenal
(HPA) axis function and ghrelin levels seems to be crucial
for maintaining homeostasis (13). However, recent studies
suggest some controversy on the ability of ghrelin to stimu-
late food intake in the absence of endogenous glucocorti-
coid. In fact, while Proulx et al. (14) claimed that ghrelin
is able to stimulate feeding in the absence of endogenous
glucocorticoid, conversely, Tung et al. (15) and Tschop et al.
(16) did not observe any ghrelin stimulatory effect on food
intake in ad libitum (AL) eating, bilateral adrenalectomized
(ADX) rats.
In the present study, we tested the hypothesis of whether
hypothalamic ghrelin treatment is able to restore normal food
intake in a rat model of ADX-induced anorexia when com-
bined with prolonged food restriction (FR). The rationale
of this experimental design is sustained by the fact that ADX
is able to reduce leptinemia (17), thus minimizing peripheral
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anorexigenic signal activity, in combination with FR-in-
duced enhanced hypothalamic NPY-ergic function (18).
Thus, these manipulations will allow the interpretation of
whether neuroendocrine, hypothalamic CRH-mediated stress
is a major factor characterizing social anorexia.
Results
Effects of Food Restriction and Surgeries
on Rat Body Weight and Peripheral Leptin Levels
Figure 1 (upper panel) shows daily 2-h food intake (be-
tween 9:00 and 11:00) of individually housed rats. As
depicted, all rats increased the amount of food eaten in 2 h,
in a time-dependent fashion, between d 1 and 7 of the food
restriction (FR) design (see Materials and Methods). Once
subjected to the FR paradigm, rats had already lost body
weight 24 h after initiation but remained at a stable level of
body weight until d 7 (Fig. 1, lower panel). On d 7, after
weighing, rats were subjected to ADX or adrenal sham oper-
ation, and implantation of iv and icv catheters. Adrenal
gland-operated rats were implanted, at the time of surgery,
with a sc placebo (sham and ADX animals) or corticoster-
one (B) pellet (ADX+B rats). As shown (Fig. 1), surgeries
induced a decline in 2-h food intake (upper panel) and,
consequently, in BW (lower panel). However, from d 10/
11 of the FR paradigm animals stabilized both daily 2-h
food intake and BW, although both groups of ADX rats
remained anorectic and lighter vs sham rats up to the expe-
rimental day (d 15). Rats subjected to our experimental
design were characterized by the following morning basal
circulating leptin concentrations (in ng/mL; mean ± SEM,
n = 6–7 rats per group): 4.45 ± 0.63 in ad libitum (AL) rats;
1.31 ± 0.33, in sham-FR rats (p < 0.05 vs AL values); 0.24
± 0.03, in ADX-FR rats (p < 0.05 vs AL and sham-FR
values); and 0.28 ± 0.07, in ADX+B-FR rats (p < 0.05 vs
AL and sham-FR values).
Effect of Ghrelin icv Administration
on 2-h Food Intake in AL and FR Rats
Figure 2 shows results of individual food intake (expressed
in relation to individual BW) in icv-treated AL rats. As
depicted, ghrelin icv administration significantly (p < 0.05
vs veh-injected rat values) stimulated 2-h food intake. Spon-
taneous 2-h food intake was several-fold higher (p < 0.05)
in FR than in AL rats, regardless of group (Fig. 2). As de-
picted, spontaneous 2-h food intake was significantly lower
(p < 0.05 vs values in sham-FR rats icv treated with veh)
in both ADX rats and ADX animals receiving corticoster-
one (B) replacement therapy (ADX+B) (Fig. 2). Finally,
sham- and ADX+B-FR rats icv-treated with ghrelin ate, in
2 h, a similar amount of food as that observed after icv veh
treatment (Fig. 2). Surprisingly, 2-h food intake was sig-
nificantly reduced (p < 0.05 vs veh-treated ADX-FR rats)
after icv ghrelin administration in ADX-FR rats (Fig. 2).
Effects of Ghrelin icv Administration and Food Intake
on Circulating Hormone Levels in Rats
Basal ghrelin levels in AL rats were not modified 2 h
after veh icv administration and food intake; however, they
resulted significantly (p < 0.05 vs respective basal values)
enhanced 2 h after ghrelin icv administration and food intake
(Fig. 3). As expected, FR rats have developed basal hyper-
ghrelinemia (p < 0.05 vs basal values in AL rats) (Fig. 3).
Among FR rats, we found that basal circulating ghrelin
concentrations were significantly (p < 0.05 vs basal sham
values) enhanced by ADX, and this effect was abolished by
B replacement therapy (Fig. 3). Basal circulating ghrelin
levels declined 2 h after both icv veh treatment and food
intake in FR rats (p < 0.05 vs respective basal values); how-
Fig. 1. Daily 2-h food intake (upper) and body weight (lower)
values in food-restricted rats before (closed circles represent intact
animals between d 1 and 7; n = 18–21 rats) and after (d 8–14;
n = 6–7 rats per group) surgeries (Sx; see Table 2). Body weights
were recorded daily before 2-h food access. Day zero body weight
values (lower) were recorded on the morning of the day when
food restriction began.
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ever, values in ADX-FR animals remained somewhat higher
(albeit not significant) than in sham- and ADX+B-FR rats
(Fig. 3). Finally, 2 h after icv ghrelin injection and food
intake circulating ghrelin levels were high, regardless of
the group examined (Fig. 3).
When AL and sham-FR rats were icv-administered with
veh, we found no changes in circulating ACTH levels 2 h
after treatment (Fig. 4, upper panel). These observations
argue in favor of effective adaptive mechanisms developed
in glucocorticoid-replete FR animals (sham- and ADX+B-
FR rats) to normalize basal circulating ACTH levels. On
the contrary, the enhanced basal ACTH levels (p < 0.05 vs
basal sham-FR rat values) characterizing ADX-FR rats
were significantly (p < 0.05 vs respective basal values) de-
creased 2 h after icv veh treatment and food intake (Fig. 4,
upper panel). Interestingly, icv ghrelin administration sig-
nificantly (p < 0.05 vs basal values) increased circulating
ACTH concentrations, 2 h after treatment and food intake,
only in groups of glucocorticoid-replete rats (Fig. 4, upper
panel).
Peripheral B concentrations (Fig. 4, lower panel) in AL
rats, were not modified 2 h after icv veh administration and
food intake, and icv ghrelin treatment increased, although
not significantly, plasma B levels 2 h after events. In sham-
FR rats basal B circulating levels were significantly (p < 0.05)
decreased 2 h after icv veh, but not ghrelin, treatment and
food intake (Fig. 4, lower panel). As expected in ADX-FR
Fig. 2. Food intake 2 h after icv administration of vehicle () or ghrelin () in ad libitum (AL) eating and in, glucocorticoid-replete (sham
and ADX+B) and -depleted (ADX), food restricted (FR) rats (n = 6–7 per group/condition). *p < 0.05 vs values in icv vehicle-treated
rats of the same group. +p < 0.05 vs values in icv vehicle-treated sham-FR rats.
Fig. 3. Circulating ghrelin levels 10 min before  and ) and
120 min after icv administration of either vehicle () or ghrelin
() in ad libitum (AL) eating and in sham, ADX, and ADX+B
food restricted (FR) rats (n = 6–7 per group/condition). *p < 0.05
vs respective basal (time −10 min) values in the same group. ♦p <
0.05 vs basal (time −10 min) values in AL rats. +p < 0.05 vs basal
(time −10 min) values in sham-FR rats.
123
123
123
123
ADX and Ghrelin-Modulated Food Intake / Spinedi et al.480 Endocrine
rats, the very low B circulating concentrations (at the lower
limit of the detection range of the assay) were not modified
2 h after food intake and either icv treatment (Fig. 4, lower
panel). Finally, ADX+B-FR rats showed a constant periph-
eral B level (expected to be in a range of 5–8 µg/dL), regard-
less of icv treatment and food intake (Fig. 4, lower panel).
Effects of Food Intake, the Glucocorticoid
Environment and icv Treatment
on Hypothalamic mRNAs Levels in Rats
Two hours after icv ghrelin treatment and food intake
in AL rats, we found that basal hypothalamic NPY mRNA
levels were unmodified compared to AL veh-treated rats
while eating (Fig. 5, upper panel). As could be expected,
this hypothalamic parameter, in basal condition, was sig-
nificantly (p < 0.05 vs values in AL rats) enhanced in all
groups of FR rats, regardless of treatments (Fig. 5, upper
panel). Two hours after icv ghrelin administration and food
intake, hypothalamic NPY mRNA levels were unchanged
(vs respective icv veh values) in sham- and ADX+B-FR rats
(Fig. 5, upper panel). Surprisingly, hypothalamic NPY mRNA
levels were significantly reduced (p < 0.05 vs veh-values)
in ADX-FR rats 2 h after icv ghrelin administration and food
intake (Fig. 5, upper panel).
Fig. 5, lower panel, shows the results of hypothalamic
CRH mRNA expression in different groups. As depicted,
similar levels of this parameter were found in AL and sham-
FR rats, regardless of treatment. As expected, they were
significantly enhanced (p < 0.05 vs AL and sham-FR rats
values) in ADX- and ADX+B-FR rats treated with veh
(Fig. 5, lower panel). Finally, 2 h after icv ghrelin treatment
and food intake, although hypothalamic CRH mRNA re-
mained high in ADX-FR rats, it was reduced (p < 0.05 vs
basal values) in ADX+B-FR rats (Fig. 5, lower panel).
Basal hypothalamic ghrelin-R1a mRNA expression (Table
1) was high (p < 0.05 vs AL-veh values) 2 h after veh ad-
ministration and food intake in sham- and ADX-FR rats;
conversely, ADX+B-FR rats showed significantly (p < 0.05)
Fig. 4. Circulating ACTH (upper) and corticosterone (lower) lev-
els 10 min before ( and  ) and 120 min after icv administration
of either vehicle () or ghrelin () in ad libitum (AL) eating and
in sham, ADX, and ADX+B food restricted (FR) rats (n = 6–7 per
group/condition). *p < 0.05 vs respective basal (time −10 min)
values in the same group. +p < 0.05 vs values, obtained in similar
condition, in sham-FR rats.
Fig. 5. Hypothalamic NPY (upper) and CRH (lower) mRNA
expression (in arbitrary units, AU), 2 h after icv administration of
vehicle () or ghrelin (), in ad libitum (AL) eating and in sham,
ADX, and ADX+B food restricted (FR) rats (n = 6–7 per group/
condition). *p < 0.05 vs vehicle values in the same group. +p <
0.05 vs vehicle values in sham-FR rats. ♦p < 0.05 vs vehicle
values in AL rats.
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lower hypothalamic ghrelin-R1a mRNA expression than
sham- and ADX-FR rats. In ADX+B-FR rats, ghrelin-R1a
mRNA expression was significantly (p < 0.05) higher 2 h
after icv treatment with ghrelin than with veh. Finally, the
expression of hypothalamic GC-R mRNA was similar in
all groups and conditions studied (Table 1).
Discussion
Ghrelin, the most relevant physiological peripheral hun-
ger signal (1), belongs to a very long list of molecules in-
volved in the control of the circuitry regulating appetite
(19). Data in the literature indicate controversy on the effec-
tiveness of adrenal gland ablation in disrupting ghrelin pro-
duction and actions (14–16). Our data demonstrate that icv
ghrelin treatment, although able to stimulate food intake in
ad libitum eating rats, has no effect on food-restricted rats
with normal HPA axis activity. Moreover, after FR, we
found a novel ghrelin role in ADX-induced anorectic rats.
In fact, hypothalamic ghrelin injection inhibited food in-
take in ADX-FR rats, even though that these animals still
expressed hypothalamic ghrelin-R1a gene.
Interestingly, corticotrope function was stimulated, al-
though to a different degree, by icv ghrelin administration
in both AL and glucocorticoid-replete-FR rats. Ghrelin is
known to enhance HPA axis function after the stimulation
of hypothalamic CRH and vasopressin secretion (20,21),
but has no direct effect on adrenal steroid output (22–24).
Thus, our data support that a normally glucocorticoid-tuned
hypothalamo–corticotrope axis is needed in order to be
directly stimulated by ghrelin.
As our data indicate, the ghrelin inhibitory effect on food
intake in ADX-FR rats seems to operate via a reduction
in hypothalamic NPY-ergic activity, while ADX-induced
enhanced CRH-ergic function remains. This probably indi-
cates that the lack of glucocorticoid could have a primary
impact, impeding dynamic changes in central CRH-ergic
function. Under these circumstances, the direct/indirect
effect of ghrelin could result in the exacerbation of the CRH
inhibitory function on NPY-ergic activity (25). Moreover,
our data agree with previous observations (26,27) indicat-
ing that hypothalamic treatment of AL rats with CRH antag-
onist enhanced NPY-induced food intake. This also con-
cords with authors who claim that NPY-stimulated food
intake can be either blocked by PVN injection of urocortin
(28) or enhanced by toxin-impaired hypothalamic CRH
function (29). In addition, while increased food intake was
found after central injection of GHRP-6 in AL rats, this
effect was accompanied, as we now observed after ghrelin,
by unchanged hypothalamic NPY mRNA expression (18).
Similarly, FR-stimulated hypothalamic NPY mRNA expres-
sion remained unmodified after icv GHRP-6 treatment (18).
Thus, these data could indicate that GHRP-6–stimulated
feeding, in FR rats, did not depend on enhanced hypothal-
amic NPY-ergic function (18). It must be stressed, how-
ever, that our FR paradigm, characterized among others by
hypoleptinemia (17,30,31), was able to enhance not only
pre- (NPY-ergic) but also post-synaptic hypothalamic orexi-
nergic effects (32). Also, our FR design increased basal
circulating ghrelin levels, while hypothalamic ghrelin-R1a
mRNA expression remained, and was even higher than in
AL rats, thus confirming that FR did not result in hypotha-
lamic downregulation of ghrelin-R1 as an interfering fac-
tor for the lack of hypothalamic ghrelin action. Moreover,
a recent study (33), although it used a different species, dem-
onstrated that central ghrelin treatment inhibited food intake
by enhancing hypothalamic CRH-ergic activity. Further-
more, this effect was fully abrogated by CRH antagonist co-
treatment, while hypothalamic NPY-ergic activity remained
similar (33).
Some authors reported that, in AL rats, prolonged ghre-
lin treatment failed to stimulate food intake if animals under-
went a previous bilateral ADX (15,16). Conversely, other
authors found that the orexigenic activity of ghrelin remained
in anorectic ADX rats, but only if animals were not pre-
viously subjected to feeding manipulations (14). These dis-
crepancies could be related to differences between experi-
mental designs (14–16). Precisely, we chose our FR design
Table 1
Hypothalamic Glucocorticoid-Receptor (GC-R) mRNA Expressiona
icv treatment                         Vehicle                             Ghrelin
Group GC-R Ghrelin-R1a GC-R Ghrelin-R1a
AL 102.9 ± 4.3 99.8 ± 8.9 106.1 ± 11.4 119.9 ± 9.7
FR
Sham 100.9 ± 9.2 142.9 ± 21.7♦ 105.9 ± 13.3 138.9 ± 16.2
ADX 114.1 ± 6.7 132.9 ± 22.5♦ 121.9 ± 10.5 114.1 ± 9.5
ADX+B 116.2 ± 7.2 68.1 ± 22.4° 121.8 ± 9.1 157.8 ± 11.9*
aTwo hours after food intake and icv treatment, in ad libitum eating (AL) and food
restricted (FR), glucocorticoid-depleted (ADX) and -replete (Sham and ADX+B), rats.
Values, expressed in arbitrary units, are the mean ± SEM (n = 5–7 hypothalami per
group). ♦p < 0.05 vs AL-veh; °p < 0.05 vs sham- and ADX-veh values; *p < 0.05 vs ADX+B-
veh values.
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partly because we were able to modulate signals allowing
ghrelin action on food intake, e.g., by developing enhanced
hypothalamic NPY-ergic function and decreasing circulat-
ing levels of leptin, while anorectic hypothalamic CRH-
ergic activity was adapted in rats with intact adrenal function
(34). Also, recent results (35) reinforce the rationale of our
FR paradigm. Because they indicate that after the fasting-
induced hypoleptinemia, a condition resembling our FR
state, a clear increase in the spike frequency of arcuate NPY/
AgRP neurons takes place, an effect fully abolished by ip
leptin administration (35). Thus, their (35) data and ours
confirm that the hypothalamic NPY network is the primary
pathway inducing appetite (36).
Our study provides additional evidence of the modula-
tion of hypothalamic CRH-ergic activity exerted by pro-
longed FR. In fact, after prolonged FR in animals with intact
adrenals, hypothalamic CRH (18,34) and GC-R mRNAs
expressions were normal (e.g., similar to that observed in
AL rats). Moreover, the stimulatory effect exerted by ADX
on basal hypothalamic CRH mRNA expression was not
reversed by the low B levels reached by the steroid replace-
ment therapy applied. To our knowledge, this is the first
report demonstrating that in 7-d ADX rats receiving low B
replacement therapy, with normal basal circulating levels
of ACTH, the hypothalamic CRH-ergic function pathway
remains enhanced. This observation could be related to the
fact that the median eminence is an important target for
rapid establishment of the negative glucocorticoid feedback
mechanism on both CRH and vasopressin secretion (37).
Thus, low B levels were effective for normalization of cor-
ticotrope function. Interestingly, while icv ghrelin treatment
did not modify hypothalamic CRH mRNA expression in
ADX-FR rats, the low B circulating levels characterizing
ADX+B-FR animals were, however, permissive enough to
reveal an inhibitory effect of icv ghrelin on CRH-ergic func-
tion, thus allowing these rats to eat as much as sham-FR
rats did.
Basal ghrelin circulating concentrations were high (vs
values in AL rats) in FR rats. The increase in basal ghrelin-
emia was even more pronounced in ADX-FR (significantly
different vs sham-FR values), an effect that was absent in
ADX+B-FR animals. These observations argue in favor of
a glucocorticoid dependency (15,16) of peripheral ghrelin
secretion in physiological and under negative balance con-
ditions. Also, the fact that in the absence (ADX-FR) or in
the presence of constant low B (ADX+B-FR) peripheral
levels, initial and final ghrelinemia were similar probably
indicates that intact functionality of the adrenals could mod-
ulate the ghrelin metabolic clearance rate. The high basal
ghrelin peripheral levels in FR rats significantly decreased
2 h after food intake and icv veh administration. This indi-
cated that acute food intake/satiety is a highly important
signal to trigger mechanisms inhibiting ghrelin release.
Interestingly, we found significant increases in ghrelin circu-
lating levels in AL and sham-FR rats after icv ghrelin admin-
istration. The latter observation probably indicates that a
ghrelin brain-to-blood passage has taken place. Data in the
literature confirm this statement, and bi-directional passage
of ghrelin across the blood–brain barrier (BBB) has been
suggested (38). This study also claims that the intact ghrelin
molecule (like the one used in our study), rather than des-
octanoyl ghrelin, is the active molecular form crossing the
BBB, from the central nervous system to the periphery.
This supports an important role that hypothalamic ghre-
lin (20,21,39) plays in regulating GH secretion and energy
balance (40).
In brief, the present study supports an important role of
hypothalamic ghrelin in the mechanisms related to chronic
hypothalamic stress-induced anorexia by inhibiting NPY-
ergic function in glucocorticoid-deprived animals subjected
to FR. Indeed, physiopathological imbalance between hypo-
thalamic NPY- and CRH-ergic activities (25,27,29) results
in eating disorders. Therefore, this novel hypothalamic ghre-
lin effect could operate by exacerbating wasting in clinical
pictures characterized by anorexia and corticoadrenal dys-
function (41–43).
Materials and Methods
Animals, Surgeries and Experimental Design
Adult male (280–330 g BW) Wistar rats were used in all
experiments. Rats were kept in a light- (lights on between
06:00 and 18:00) and temperature- (20–22°C) controlled
room, and caged (five rats per cage) for 7 d with free access
to Purina Chow Diet and water. The following day (d 1 of
different food intake protocols) at 07:00 h rats were weighed,
individually housed in plastic cages, and left undisturbed
without food availability. At 09:00 h, food (50 g) was pro-
vided, and the remaining food withdrawn at 11:00 h. The
grams of food eaten in a 2-h period were then calculated.
On this basis, two groups of rats emerged, the first one
formed by rats eating AL for 15 d, while the second group
was subjected to a previously described FR paradigm (30,
44). Briefly, rats have had daily access to food between
09:00 and 11:00 h for a period of 15 d. Daily individual
2-h food intake and BW (registered at 07:00 h) values were
recorded from d 1 to d 15 of the experimental design. Rats
(AL and FR) were implanted, under ketamine anesthesia,
with both icv (coordinates from the point of bregma, in mm,
were: 1.0 posterior, 1.8 lateral, and 3.5 deep) and iv cath-
eters (30) on d 7 of the food intake protocol. AL rats were
then returned to their home cages and continued in similar
conditions to those described before surgeries. Addition-
ally, on the same day (d 7) of the paradigm, FR rats were
subjected to either adrenal gland sham-operation (sham) or
bilateral ADX (performed by the dorsal approach). At the
time of surgery, whereas sham- and ADX-FR rats were sc
implanted with a placebo pellet, ADX+B animals were sc
ADX and Ghrelin-Modulated Food Intake / Spinedi et al.Vol. 29, No. 3 483
implanted with 75 mg B pellets (Innovative Research of
America, Toledo, Ohio, USA) (ADX+B-FR) (31). Animals
were returned to their cages and continued with the FR
paradigm. ADX- and ADX+B-FR rats drank NaCl 0.9%
until the end of experimentation. On d 15 of the food intake
protocols (AL and FR), animals were iv bled 10 min before
(basal) and 120 min after icv injection (performed at 09:00
h) of 2 µL of sterile saline solution either alone (vehicle;
veh) or containing ghrelin (Phoenix Pharmaceuticals Inc.;
1 µg). Animals were then sacrificed by decapitation and
medial basal hypothalamus (MBH; containing the median
eminence) tissues were dissected (37) and kept frozen (−80°C)
until measurements. The amount of food eaten during the
2-h period after icv treatment was recorded. A summary of
our experimental design is depicted in Table 2.
Hormone Measurements
Peripheral ghrelin concentrations were assayed by a spe-
cific radioimmunoassay (RIA) with a kit supplied by Phoe-
nix Pharmaceuticals Inc. (cat. no. RK-031-31). The stan-
dard curve ranged between 1 and 1280 pg/tube; intra- and
interassay coefficients of variation (CVs) were 3–5 and 8–
11%, respectively. Circulating ACTH concentrations were
measured by a commercial immunoradiometric assay (cat.
no. 40-2195, Nichols Institute Diagnostics, San Juan Capis-
trano, CA, USA) with a standard curve ranging between
5 and 1400 pg/mL and with intra- and interassay CVs of
3–4 and 6–8%, respectively. Plasma concentrations of B
were evaluated by a specific RIA described previously (37),
the standard curve ranging between 1 and 250 µg/dL, and
intra- and interassay CVs were 4–6 and 8–10%, respec-
tively. Peripheral leptin concentrations were determined
by a specific RIA kit supplied by Linco Research Inc. (St.
Charles, MO, USA; cat. no. RL-83K). The standard curve
of this assay ranged between 0.5 and 25 ng/mL, intra- and
interassay CVs were 2–5 and 3–6%, respectively.
Hypothalamic RNA Isolation and Analysis
Total RNA was extracted from MBH tissues, using a
commercially available reagent (TriPure®, Roche Diag-
nostics, cat. no. 11667165001). The yield of extraction was
assessed by measuring light absorbency at 260 nm, and the
quality of RNA by calculating the ratio of the absorbencies
measured at 260 and 280 nm. Reverse transcription was
performed, starting with 2 µg of total RNA and using ran-
dom primers and the enzyme SuperScript™ II Reverse
Transcriptase (Invitrogen, cat. no. 18064-022). The rela-
tive gene expression of NPY, ghrelin-R1a, GC-R, and CRH
was assessed by real-time quantitative RT-PCR, using the
LigthCycler® technology (Roche Diagnostics, Rotkreuz,
Switzerland) with the Quantitect Sybr® Green PCR Kit
(Qiagen, Hilden, Germany) as previously described (45).
The following primer pairs, designed in our laboratory and
synthesized by Microsynth (Windish, Switzerland), were
used for the amplification: NPY (F) 5'-TCC GCT CTG
CGA CAC TAC AT-3', and (R) 5'-TGC TTT CTC TCA
TTA AGA GAT CTG-3' (100 bp; GenBank accession num-
ber NM 012614); ghrelin-R1a (F) 5'-ACT GTG CTC TAC
AGT CTC ATC GGG A-3', and (R) 5'-CCA CCA CAG
CAA GCA TCT TCA CT-3' (118 bp; GenBank accession
number NM 032075); GC-R (F) 5'-TTC AGG ATG TCA
TTA CGG GGT-3', and (R) 5'-CCT GAA GAC ATT TCC
GAT AGC G-3' (167 bp; GenBank accession number Y
12264); CRH (F) 5'-CTG CCA AGG GAG GAG AAG
GTA G-3', and (R) 5'-TCA GAA TCG GCT GAG GTT
GCT G-3' (188 bp; GenBank accession number NM 031019);
β-actin (F) 5'-CGT TGA CAT CCG TAA AGA-3', and (R)
5'-TAG AGC CAC CAA TCC ACA C-3' (176 bp; GenBank
accession number NM 031144). For quantification purposes,
NPY, ghrelin-R1a, GC-R, and CRH mRNA levels were
always reported to the level of β-actin mRNA in the same
sample. Different dilutions of the samples were tested in
preliminary experiments to ensure that quantification
would be performed within the linear part of the amplifica-
tion. Following this test, all samples were quantified in at
least two different runs, to obtain an interassay CV < 10%.
Relative expression was then determined using crossing point
values and amplification efficiencies of the target gene and
the reference gene.
Analysis of Data
Results are expressed as the mean ± SEM. Data for circu-
lating hormone concentrations were analyzed by multiple
factor ANOVA, followed by Student–Newman–Keul’s test
(46) for comparison of different mean values. The non-
parametric Mann–Whitney test (46) was used for analysis
of data obtained from hypothalamic mRNA expression.
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Table 2
Brief Summary of the Experimental Design
Groups
AL Ad libitum eating, between d 1–15.
FR Eating with daily free food availability for a 2-h period
only, between d 1 and 15.
Surgeries
AL icv and iv catheters on d 7 of the food intake protocol.
FR Sham operation of adrenal glands or bilateral adrenalectomy,
combined with icv, iv catheters, and sc pellet (placebo or
B) implantations on d 7 of the food intake protocol.
Experimental day
On d 15, animals were bled before (−10 min; basal) and
2 h after icv treatment, while rats had free access to food.
Rats were sacrificed immediately after the last bleeding
and hypothalamic tissues were immediately dissected.
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